UPDATE: Cantor Fitzgerald Reiterates Overweight On Acadia Pharmaceuticals, Raises Target To $40 As Firm Notes 'enhanced conviction, due to recent diligence with multiple KOLs, for pimavanserin as treatment for negative symptoms in schizophrenia pts'